Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

iShares Global Healthcare ETF

103.63
+0.46000.45%
Volume:10.77K
Turnover:1.12M
Market Cap:4.37B
PE:-100.78
High:103.69
Open:103.53
Low:103.34
Close:103.17
52wk High:107.69
52wk Low:90.24
Shares:42.15M
Float Shares:42.15M
Volume Ratio:0.89
T/O Rate:0.03%
Dividend:1.44
Dividend Rate:1.39%
EPS(TTM):-1.0283
EPS(LYR):-1.0283
ROE:-8.66%
ROA:0.90%
PB:1.13
PE(LYR):-100.78

Loading ...

OverviewCompanyNewsFilings

JPMorgan Adjusts Price Target on Merck & Co. to $165 From $150, Maintains Overweight Rating

MT Newswires Live
·
Oct 05

Wall Street's US$10 bil India hospital bet sparks a fight over bills

Ranjani Raghavan & Anto Antony / Bloomberg
·
Oct 05

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

TIPRANKS
·
Oct 03

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 03

AbbVie Joins US Government Pilot to Test Drug Discount Rebates

Reuters
·
Oct 03

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 03

Abbvie-from Jan 1, 2027, Covered Entities to Submit Claims to GET 340B Pricing Through Beacon on 340B-Eligible Dispenses of Imbruvica, Linzess,Vraylar

THOMSON REUTERS
·
Oct 03

Abbvie - Approved to Participate in Federal 340B Rebate Model Pilot Program

THOMSON REUTERS
·
Oct 03

Former Eli Lilly Exec Sells Wyoming Estate for Close to $39.5 Million

Dow Jones
·
Oct 03

Why Medtronic's $4 Billion MiniMed Exchange Offer is Losing Its Allure

Dow Jones
·
Oct 03

Eli Lilly announces FDA approves additional indication for Jaypirca

TIPRANKS
·
Oct 03

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
Oct 03

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
Oct 03

Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says

MT Newswires Live
·
Oct 03

Innova Captab Files Scrutinizer’s Report and Voting Results for 22nd AGM

TIPRANKS
·
Oct 03

AbbVie’s Venetoclax AML Study in Greece: What the Latest Update Means for Investors

TIPRANKS
·
Oct 03

Correction: Top Midday Decliners

MT Newswires Live
·
Oct 02

Johnson & Johnson announces two-year data from Phase 3 ICONIC-TOTAL study

TIPRANKS
·
Oct 02

Johnson & Johnson Says Icotyde Sustains Psoriasis Skin Clearance Through 2 Years in Phase 3 Iconic-TOTAL Study

Reuters
·
Oct 02

J&J - Icotyde-Treated Patients Show 70% Clear or Almost Clear Skin at Week 112

THOMSON REUTERS
·
Oct 02
More